Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 112 posts found.

Biogen boosts ophthalmology portfolio with $800m acquisition of gene therapy firm Nightstar

March 4, 2019
Sales and Marketing Biogen, Nightstar, acquisition, pharma

Biogen has announced it has inked an agreement to acquire clinical-stage gene therapy firm Nightstar for a total value of …

News
shutterstock_292920209

UCB and Biogen’s lupus drug falls short at Phase 2b

October 24, 2018
Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure

The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet …

News

Samsung and Bioepis launch third Humira biosimilar in Europe

October 17, 2018
Research and Development, Sales and Marketing Amgen, Biogen, Humira, Imraldi, Samusng Bioepis, pharma

Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of …

News
msd

MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar

October 8, 2018
Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis

American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department …

News
14680814113_e81affc144_z_1

UK Health Secretary Matt Hancock rallies against ‘rip off’ pharma companies

September 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Matt Hancock, NICE, Vertex, pharma, pricing

British Health Secretary Matt Hancock has said that pharmaceutical companies are trying to “rip off taxpayers” and that big business …

News
biogen_austria_238

NICE rejects Biogen’s spinal muscular dystrophy drug Spinraza after long delay

August 14, 2018
Manufacturing and Production, Sales and Marketing Biogen, NICE, Spinraza, UK, pharma, spinal muscular dystrophy

UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available …

News
ptc

PTC Therapeutics’ results in SMA has Biogen nervous

June 19, 2018
Manufacturing and Production, Research and Development Biogen, PTC Therapeutics, biotech, drugs, pharma, pharmaceutical

Biogen currently has the only product on the market approved to treat spinal muscular atrophy (SMA), in Spinraza, and that …

News
biogen_idec_hillerod_2008

Biogen boosts pipeline with $1bn Ionis deal

April 23, 2018
Sales and Marketing Biogen, Ionis, Spinraza, biotech, drugs, pharma, pharmaceutical

Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …

News
humira_abbott__4

Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar

April 6, 2018
Medical Communications, Sales and Marketing AbbVie, Biogen, Humira, Imraldi, Samsung Bioepis, biosimilar, pharma

Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie …

News
biology-think-networking-physiology-brain-anatomy-2676370

Pfizer begins sell-off, shedding CNS drug to Biogen for $590m

March 13, 2018
Manufacturing and Production, Sales and Marketing Biogen, CNS, Pfizer, biotech, drugs, pharma, pharmaceutical

Pfizer’s decision to back out of the neuroscience space was a strategic move that send shudders through the entire industry, …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

March 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Celgene, EMA, Gilead, HIV, Herceptin, Japan, NHS, Ontruzant, Sanofi, opioid crisis, opioids, pharma, real world data, top ten, zinbryta

After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter …

News

Abbvie and Biogen pull MS drug Zinbryta following urgent EMA safety review

March 5, 2018
Sales and Marketing AQbbvie, Biogen, EMA, Europe, mulyiple sclerosis, pharma, zinbryta

Biogen and Abbvie have announced their intention to voluntarily withdraw their multiple sclerosis therapy Zinbryta (daclizumab) from all global markets …

News
biogen_austria_238

Biogen shares hit by key Alzheimer’s drug concerns

February 15, 2018
Research and Development Alzheimer's, Biogen, MSD, Merck, biotech, drugs, pharma, pharmaceutical

Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its …

News
biogen_idec_hillerod_2008

Biogen halts Tysabri trial after failure in acute ischemic stroke

February 8, 2018
Research and Development Biogen, Tysabri, multiple sclerosis, pharma, stroke, trial failure

Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute …

News

Biogen announces acquisition along with financials, but it’s tiny

January 26, 2018
Medical Communications, Sales and Marketing Biogen, Karyopharm, biotech, drugs, pharma, pharmaceutical

Biogen is one those companies, like Sanofi until its recent Bioverativ acquisition, that has real pressure to make a big …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023